TrialBlood2021

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

Franck Morschhauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.